Aslan Serkan, Guner Ahmet, Uysal Hande, Ertürk Mehmet
Department of Cardiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Türkiye.
Turk Gogus Kalp Damar Cerrahisi Derg. 2025 Apr 30;33(2):247-250. doi: 10.5606/tgkdc.dergisi.2025.25825. eCollection 2025 Apr.
Structural valve deterioration in surgical bioprostheses may require redo valve surgery, which is associated with significant operative mortality and poor long-term survival. As an alternative treatment option, valve-in-valve (ViV) transcatheter mitral valve replacement (TMVR) has emerged for patients with symptomatic and severely degenerated bioprosthetic valves who are at high risk for redo cardiac surgery. This case report describes the first case of transseptal valve-in-valve-transcatheter mitral valve replacement in an 85-year-old female patient in Türkiye. The patient had a degenerated mitral bioprosthesis and was at high surgical risk. The patient had previously undergone valve-in-valve transcatheter aortic valve replacement. The procedure was completed successfully, and there were no complications during the postprocedural course.
外科生物瓣膜的结构瓣膜退变可能需要再次进行瓣膜手术,这与显著的手术死亡率和较差的长期生存率相关。作为一种替代治疗选择,对于有症状且生物瓣膜严重退变、再次心脏手术风险高的患者,经导管二尖瓣置换术(TMVR)的瓣中瓣(ViV)技术应运而生。本病例报告描述了土耳其一名85岁女性患者首次经房间隔瓣中瓣经导管二尖瓣置换术的情况。该患者有一个退变的二尖瓣生物瓣膜,手术风险高。该患者此前曾接受过瓣中瓣经导管主动脉瓣置换术。手术成功完成,术后过程中未出现并发症。